Insulin therapy and quality of life. A review

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue SUPPL. 1, 2009, Pages

  Pouwer, François ^a,b   Hermanns, Norbert ^c  

^a TILBURG UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Research Institute of the Diabetes Academy Mergentheim   (Germany)

Author keywords

Diabetes mellitus; Insulin; Insulin infusion systems; Long acting; NPH; Quality of life; Review

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DEPRESSION; DRUG TOLERABILITY; EMOTIONAL STRESS; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; KIDNEY DISEASE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RETINOPATHY;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INTERVIEWS AS TOPIC; PERSONALITY; PUBLICATIONS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIAL VALUES;

EID: 73349099345     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.981     Document Type: Conference Paper

References (42)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl JMed 1993; 329: 977-986.
2. UK Prospective Diabetes Study [UKPDS] Group. Intensive blood-glucose control with conventional treatment and risk of complications in patients with type 2 diabetes [UKPDS 33]. Lancet 1998; 352: 837-853.
3. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15: 205-218.
4. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of co-morbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24: 1069-1078.
5. Pouwer F, Beekman ATF, Nijpels G, et al. Rates and risks for co-morbid depression in patients with type 2 diabetes mellitus: results from a community-based study. Diabetologia 2003; 46: 892-898.
6. Hermanns N, Scheff C, Kulzer B, et al. Association of glucose levels and glucose variability with mood in type 1 diabetic patients. Diabetologia 2007; 50: 930-933.
7. Zhang X, Norris SL, Chowdhury FM, Gregg EW, Zhang P. The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. Med Care 2007; 45: 820-834.
8. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25(3): 245-254.
9. Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. Diabetes Metab Res Rev 2004; 20(Suppl. 2): S32-S42.
10. Snoek FJ. Self management of diabetes. BMJ 2007; 335: 458-459.
11. Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.
12. Hunt SM, Mc Kenna SP, Mc Ewan J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 1981; 15: 221-229.
13. Ware JE. Improvements in short-form measures of health status: introduction to a series. J Clin Epidemiol 2008; 61: 1-5.
14. EuroQolGroup. EuroQoL - a newfacility for themeasurement of health-related quality of life. Health Policy 1990; 16: 199-208.
15. UKPDS Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22: 1125-1136.
16. McNair DM, Lorr M, Droppleman LF. EdITS Manual: Pro file of Mood States. Educational and Industrial Testing Service: San Diego, CA, 1981.
17. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982; 21: 1-16.
18. Polonsky WH. Understanding and assessing diabetes-specific quality of life. Diabetes Spectrum 2000; 13: 36-41.
19. El Achhab Y, Nejjari C, Chikri M, Lyoussi B. Disease-specific health-related quality of life instruments among adults diabetic: a systematic review. Diabetes Res Clin Pract 2008; 80: 171-184.
20. De Wit M, Delemarre-van de Waal HA, Pouwer F, Gemke RJ, Snoek FJ. Monitoring health related quality of life in adolescents with diabetes: a review of measures. Arch Dis Child 2007; 92: 434-439.
21. Snoek FJ, Pouwer F, Welch GW, Polonsky WH. Diabetes-related emotional distress in Dutch and U.S. diabetic patients: crosscultural validity of the problem areas in diabetes scale. Diabetes Care 2000; 23: 1305-1309.
22. Bradley C, Plowright R, Stewart J, Valentine J, Witthaus E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes 2007; 5: 57.
23. Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. Health Qual Life Outcomes 2007; 5: 69.
24. Kohlmann T, Moock J. Patientenzufriedenheit bei Diabetes mellitus - Messinstrumente und Ergebnisse. Patient satisfaction in diabetes mellitus-measures and results. Dtsch Med Wochenschr 2008; 133(Suppl. 4): S120-S123.
25. Mollema ED, Snoek FJ, Pouwer F, Heine RJ, van der Ploeg HM. Diabetes Fear of Injecting and Self-Testing Questionnaire: a psychometric evaluation. Diabetes Care 2000; 23: 765-769.
26. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 1994; 11(3): 253-261.
27. Adriaanse MC, Pouwer F, Dekker JM, et al. Diabetes-related symptom distress in association with glucose metabolism and co-morbidity: the Hoorn Study. Diabetes Care 2008; 31(12): 2268-2270.
28. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543-2545.
29. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165: 1337-1344.
30. Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008; 31: 1112-1117.
31. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; (2): CD005613.
32. Holman RR, Thorne KI, Farmer AJ, et al, 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl JMed 2007; 357: 1716-1730.
33. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin Glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-1084.
34. Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. Diabet Med 2007; 24: 607-617.
35. Speight J, Shaw JAM. Does one size really fit all? Only by considering individual preferences and priorities will the true impact of insulin pump therapy on quality of life be determined. Diabet Med 2007; 24: 693-695.
36. Nicolucci A, Maione A, Franciosi M, et al, Vitacolonna E EQuality Study Group. Evaluation of QUALITY of Life and Costs in Diabetes Type 1. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 2008; 25: 213-220.
37. Hoogma RP, Hammond PJ, Gomis R, et al, 5-Nations Study Group. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006; 23: 141-147.
38. Pánkowska E, Bxazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009; 10(1): 52-58.
39. Opipari-Arrigan L, Fredericks EM, Burkhart N, Dale L, Hodge M, Foster C. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes 2007; 8: 377-383.
40. Nuboer R, Borsboom GJ, Zoethout JA, Koot HM, Bruining J. Effects of insulin pump vs. injection treatment on quality of life and impact of disease in children with type 1 diabetes mellitus in a randomized, prospective comparison. Pediatr Diabetes 2008; 9(4 Pt 1): 291-296.
41. Makine C, Karşidaǧ Ç, Kadioǧlu P, et al. Symptoms of depression and diabetes-specific emotional distress are associated with a negative appraisal of insulin therapy in insulin-naïve patients with Types 2 diabetes mellitus. A study from the European Depression in Diabetes (EDID) Research Consortium. Diabet Med 2009; 26(1): 28-33.
42. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79.